EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	5	"2005020825"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/12/08 14:06
L2	2	"20050020825"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/12/08 14:07
L3	2	"20050031588"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/12/08 14:09
L4	7	"2004002999"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/12/08 14:10
L5	6	"2004003000"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/12/08 14:40
L6	614	514/43.ccls.	US-PGPUB; USPAT	OR	ON	2006/12/08 14:40
L7	787	514/49.ccls.	US-PGPUB; USPAT	OR	ON	2006/12/08 14:40
L8	338	536/28.5.ccls.	US-PGPUB; USPAT	OR	ON	2006/12/08 14:40

10/607,909

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  AUG 09  INSPEC enhanced with 1898-1968 archive
 NEWS  4  AUG 28  ADISCTI Reloaded and Enhanced
 NEWS  5  AUG 30  CA(SM)/CAplus(SM) Austrian patent law changes
 NEWS  6  SEP 11  CA/CAplus enhanced with more pre-1907 records
 NEWS  7  SEP 21  CA/CAplus fields enhanced with simultaneous left and right
                  truncation
 NEWS  8  SEP 25  CA(SM)/CAplus(SM) display of CA Lexicon enhanced
 NEWS  9  SEP 25  CAS REGISTRY(SM) no longer includes Concord 3D coordinates
 NEWS 10  SEP 25  CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
 NEWS 11  SEP 28  CEABA-VTB classification code fields reloaded with new
                  classification scheme
 NEWS 12  OCT 19  LOGOFF HOLD duration extended to 120 minutes
 NEWS 13  OCT 19  E-mail format enhanced
 NEWS 14  OCT 23  Option to turn off MARPAT highlighting enhancements available
 NEWS 15  OCT 23  CAS Registry Number crossover limit increased to 300,000 in
                  multiple databases
 NEWS 16  OCT 23  The Derwent World Patents Index suite of databases on STN
                  has been enhanced and reloaded
 NEWS 17  OCT 30  CHEMLIST enhanced with new search and display field
 NEWS 18  NOV 03  JAPIO enhanced with IPC 8 features and functionality
 NEWS 19  NOV 10  CA/CAplus F-Term thesaurus enhanced
 NEWS 20  NOV 10  STN Express with Discover! free maintenance release Version
                  8.01c now available
 NEWS 21  NOV 13  CA/CAplus pre-1967 chemical substance index entries enhanced
                  with preparation role
 NEWS 22  NOV 20  CAS Registry Number crossover limit increased to 300,000 in
                  additional databases
 NEWS 23  NOV 20  CA/CAplus to MARPAT accession number crossover limit increased
                  to 50,000
 NEWS 24  NOV 20  CA/CAplus patent kind codes will be updated
 NEWS 25  DEC 01  CAS REGISTRY updated with new ambiguity codes

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available
```

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:51:27 ON 08 DEC 2006

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

McIntosh

FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 13:51:54 ON 08 DEC 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 DEC 2006 HIGHEST RN 915067-95-7
DICTIONARY FILE UPDATES: 7 DEC 2006 HIGHEST RN 915067-95-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10607909.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 13:52:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 15 TO ITERATE

100.0% PROCESSED 15 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

McIntosh

```
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           68 TO      532
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:52:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      257 TO ITERATE

100.0% PROCESSED      257 ITERATIONS                              30 ANSWERS
SEARCH TIME: 00.00.01

L3           30 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   166.94     167.15

FILE 'CAPLUS' ENTERED AT 13:52:32 ON 08 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 8 Dec 2006  VOL 145 ISS 25
FILE LAST UPDATED: 7 Dec 2006  (20061207/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 13
L4            16 L3

=> d bib abs hitstr 1-16 14

L4   ANSWER 1 OF 16  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2006:1086375  CAPLUS
TI   Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of
     2'-C-methylcytidine, the active component of valopicitabine
AU   Coelmont, Lotte; Paeshuyse, Jan; Windisch, Marc P.; De Clercq, Erik;
     Bartenschlager, Ralf; Neyts, Johan
CS   Rega Institute for Medical Research, KULeuven, Louvain, 3000, Belg.
SO   Antimicrobial Agents and Chemotherapy (2006), 50(10), 3444-3446
     CODEN: AMACCQ; ISSN: 0066-4804
PB   American Society for Microbiology
DT   Journal
LA   English
AB   Ribavirin antagonizes the in vitro anti-hepatitis C virus (HCV) activity
     of the pyrimidine nucleoside analog 2'-C-methylcytidine, the active
     component of the exptl. anti-HCV drug valopicitabine.  In contrast, the
     combination of ribavirin with either the purine nucleoside analog
     2'-C-methyladenosine or the HCV protease inhibitor VX-950 resulted in an
     additive antiviral activity.  These findings may have implications when
     planning clin. studies with valopicitabine.
IT   INDEXING IN PROGRESS
IT   640281-90-9D, Valopicitabine, metabolite
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (ribavirin antagonizes anti-hepatitis C virus activity of
        2'-C-methylcytidine, active component of valopicitabine)
RN   640281-90-9  CAPLUS
```

CN L-Valine, 3'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:1011471 CAPLUS
DN 145:363620
TI Pharmaceutical compositions comprising ribofuranosylcytidine derivatives
IN Jores, Katja; Meyer, Andreas
PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SO PCT Int. Appl., 14pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006100087	A2	20060928	WO 2006-EP2693	20060323

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-664733P P 20050324

AB A pharmaceutical composition and granules are prepared by a wet granulation process. The pharmaceutical composition and granulates contain a therapeutic compound, e.g., the 3'-L-valine ester of β-D-2'-C-methylribofuranosylcytidine and its salts, esters, prodrugs or derivs. Tablets containing the above compound were prepared by wet granulation.

IT 640281-90-9 640725-71-9
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. comprising ribofuranosylcytidine derivs.)

RN 640281-90-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 640725-71-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

L4 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:981749 CAPLUS
DN 145:335928
TI Preparation of 1,5-dihydro-3-hydroxy-2H-pyrrol-2-ones as Mdm2 protein modulators
IN Weber, Lutz
PA Germany
SO Ger. Offen., 11pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 102005012681	A1	20060921	DE 2005-102005012681	20050318
PRAI DE 2005-102005012681		20050318		

OS MARPAT 145:335928
GI



I II

AB Title compds. I [R1, R2 = cycloalkyl, heteroaryl, aryl, etc.; R3 = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts were prepared For example, coupling of carboxylic acid II [X = OH] and 2-methoxyethylamine afforded amide II [X = NHCH2CH2OCH3]. Compds. I are are noted as Mdm2 protein modulators (no data provided).
IT 640281-90-9, Valopicitabine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicaments with; preparation of 3-hydroxy-2H-pyrrolones as Mdm2 protein modulators)
RN 640281-90-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:976176 CAPLUS
DN 145:335951
TI Tetrahydroisoquinolin-1-ones as HDM2 ligands, their preparation, pharmaceutical compositions, and use for the treatment of cancer
IN Weber, Lutz
PA Germany
SO PCT Int. Appl., 42pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006097323	A1	20060921	WO 2006-EP2471	20060317

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI DE 2005-102005012680 A 20050318
OS MARPAT 145:335951
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. according to formula I, which are HDM2 protein ligands, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy. In compds. I, R1 is selected from (un)substituted morpholinyl, (un)substituted pyrrolidinyl, (un)substituted piperazinyl, OR5, and NR5R6, where R5 and R6 are independently selected from H, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; R2 and R3 are independently selected from aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R4 is selected from H, OH, halo, nitro, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, and NR7R8, where R7 and R8 are independently selected from H, lower alkyl, lower alkoxyalkyl, heterocyclyl, aryl, and heteroaryl. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I, optionally in combination with a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment of cancer. Condensation of 4-chlorobenzaldehyde with 4-chlorobenzylamine followed by heterocyclization with homophthalic anhydride gave isoquinolinonecarboxylic acid II, which was amidated with 2-methoxyethylamine to give isoquinolinone III. The compds. of the invention are ligands of HDM2 (no data).
IT 640281-90-9, Valopicitabine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of tetrahydroisoquinolinones as HDM2 ligands for the treatment of cancer)
RN 640281-90-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:894484 CAPLUS
DN 145:285094
TI Glucosidase inhibitor combinations with adjunctive therapies for treating or preventing Flaviviridae infections
IN Dugourd, Dominique; Rubinchik, Evelina; Clement, Jacob; Friedland, Hillel David
PA Migenix Inc., Can.
SO U.S. Pat. Appl. Publ., 69pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006194835	A1	20060831	US 2006-351885	20060209
WO 2006096285	A2	20060914	WO 2006-US4927	20060209

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-651910P P 20050209
US 2005-664297P P 20050321
US 2005-735464P P 20051112

GI



AB The present disclosure relates generally to compns. having a glucosidase inhibitor [castanospermine (I) or a derivative thereof, such as celgosivir] in combination with adjunctive therapies of compds. that alter immune function (such as interferon) and compds. that alter viral replication (such as nucleoside analogs like ribavirin), which can be used to treat or prevent infections caused by or associated with a virus of the Flaviviridae family, particularly infections caused by or associated with Hepatitis C virus (HCV). Examples include synergy of castanospermine or celgosivir in combination with other drugs such as interferons in a checkboard approach.

IT 640725-71-9, NM283
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(glucosidase inhibitor combinations with adjunctive therapies for treating or preventing Flaviviridae infections)
RN 640725-71-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

L4 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:425398 CAPLUS
DN 145:39734
TI Nucleoside analog inhibitors of hepatitis C virus replication
AU Carroll, S. S.; Olsen, D. B.
CS Department of Antiviral Research, Merck Research Laboratories, West Point, PA, 19486, USA
SO Infectious Disorders: Drug Targets (2006), 6(1), 17-29
CODEN: IDDTAD; ISSN: 1871-5265
PB Bentham Science Publishers Ltd.
DT Journal; General Review
LA English
AB A review. Of the 30 compds. currently marketed in the United States for treatment of viral infections, 15 are nucleoside analogs, demonstrating the utility of this class of compound as a source of antiviral drugs. The success of nucleoside analogs in treating other viral infections provides a compelling rationale for the significant effort that is currently being devoted to the discovery and development of nucleoside analogs to treat infection by hepatitis C virus (HCV) that may lead to improvements in response rates compared to currently available therapies. Several different approaches were adopted to identify promising analogs, including the use of surrogate viruses in cell culture assays, screening in the cell-based bicistronic HCV replicon assay, and screening nucleoside triphosphates for the ability to inhibit the activity of the HCV RNA-dependent RNA polymerase in vitro. Several classes of ribonucleoside analogs with modifications of the ribose inhibit HCV replication. Nucleoside analogs incorporating a 2'-C-Me modification are potent inhibitors in the replicon assay in the absence of cytotoxicity, and appear to exert their inhibition by acting as functional chain terminators of RNA synthesis. NM283, a prodrug of 2'-C-methylcytidine, has entered clin. trials and demonstrated viral load redns. in subjects infected with genotype 1 HCV, a genotype known to be difficult to treat effectively with currently approved therapies. Overall, results to date offer encouragement that improved therapies to treat HCV infection including newly developed nucleoside analogs may become available within the next few years.
IT 640725-71-9, NM 283
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleoside analog inhibitors of hepatitis C virus replication)
RN 640725-71-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:342840 CAPLUS
DN 144:381956
TI Combination antiviral compositions comprising castanospermine and use for the treatment and prevention of infections caused by or associated with a virus of the Flaviviridae family
IN Dugourd, Dominique
PA Migenix Inc., Can.
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006037227	A1	20060413	WO 2005-CA1528	20051006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006093577	A1	20060504	US 2005-244811	20051006
PRAI US 2004-616787P	P	20041006		

AB The invention discloses the use of castanospermine in combination with another therapeutic agent to treat or prevent infections caused by or associated with a virus of the Flaviviridae family, particularly infections caused by or associated with Hepatitis C virus (HCV), and to the use of such compds. to examine the biol. mechanisms of HCV infection.
IT 882489-96-5
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(castanospermine-containing combination antiviral compns., and use for treatment of Flaviviridae infections)
RN 882489-96-5 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, mixt. with (1S,6S,7R,8R,8aR)-octahydro-1,6,7,8-indolizinetetrol (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 79831-76-8
CMF C8 H15 N O4

Absolute stereochemistry. Rotation (+).



IT 640281-90-9, Valopicitabine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(castanospermine-containing combination antiviral compns., and use for treatment of Flaviviridae infections)
RN 640281-90-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:149315 CAPLUS
DN 144:205728
TI Methods using a Type II interferon receptor agonist alone or in combination with a direct antiviral drug for treating hepatitis C virus infection
IN Blatt, Lawrence M.
PA Intermune, Inc., USA
SO PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006016930	A2	20060216	WO 2005-US16927	20050513
WO 2006016930	A3	20060803		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,

NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,
KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM

PRAI US 2004-571322P P 20040514

AB The invention provides methods for treating hepatitis C virus (HCV) infection; methods for reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods for reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clin. outcomes, in patients suffering from HCV infection. The methods generally involve administering to the individual a Type II interferon receptor agonist alone or in combination with a direct antiviral drug.

IT 640725-71-9, NM 283
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type II interferon receptor agonist alone or in combination with direct antiviral drug for treating hepatitis C virus infection)

RN 640725-71-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1151389 CAPLUS

DN 145:271979

TI NM 283, an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine

AU Pierra, C.; Benzaria, S.; Amador, A.; Moussa, A.; Mathieu, S.; Storer, R.; Gosselin, G.

CS Laboratoire Cooperatif Idenix, CNRS, Universite Montpellier II, Montpellier, 5, Fr.

SO Nucleosides, Nucleotides & Nucleic Acids (2005), 24(5-7), 767-770
CODEN: NNNAFY; ISSN: 1525-7770

PB Taylor & Francis, Inc.

DT Journal

LA English

OS CASREACT 145:271979

AB In order to improve the oral bioavailability of 2'-C-methylcytidine, a potent anti-HCV agent, the corresponding 3'-O-L-valinyl ester derivative (NM 283) has been synthesized. Based on its ease of synthesis and its physicochem. properties, NM 283 has emerged as a promising antiviral drug for treatment of chronic HCV infection.

IT 640725-71-9P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prodrug; preparation of NM 283 as efficient prodrug of potent anti-HCV agent 2'-C-methylcytidine)

RN 640725-71-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:684531 CAPLUS
DN 143:431740
TI Emerging drugs for chronic hepatitis C
AU Bhopale, Girish Mahadeorao; Nanda, Rabindra Kumar
CS Research and Development Division, Hindustan Antibiotics Limited, Pimpri, Pune, 411018, India
SO Hepatology Research (2005), 32(3), 146-153
CODEN: HPRSFM; ISSN: 1386-6346
PB Elsevier B.V.
DT Journal; General Review
LA English
AB A review. Hepatitis C virus (HCV) is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide. A combination therapy comprising pegylated interferon and ribavirin currently represents the most effective therapy for chronic HCV infection. The limitations of this current therapy mainly its efficacy and significant side effects have prompted the development of new drugs. Few categories of therapeutic agents appear promising for future therapy, e.g. novel interferons, ribavirin analogs, antisense oligonucleotides, short interfering RNAs, ribozymes, enzyme inhibitors, immunomodulatory agents, antifibrotic agents, therapeutic vaccines and antibodies. Few drugs belong to afore-mentioned categories have already reached the different clin. phases of development. The present article highlights the status of current available therapies and emerging drugs for the treatment of hepatitis C.
IT 640725-71-9, NM 283
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NM283 proved promising therapeutic effect in treating chronic hepatitis C patient)
RN 640725-71-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RE.CNT 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:216597 CAPLUS
DN 142:291323
TI Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
IN Hardee, Greg; Dellamary, Luis
PA Isis Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 217 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005020885	A2	20050310	WO 2004-US16196	20040521
	WO 2005020885	A3	20050804		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-472774P P 20030521
AB The invention provides compns. and methods for treating a coronavirus infection, especially a SARS CoV infection. The compns. comprise an antiviral nucleoside or mimetic thereof, or an antiviral antisense agent, in a form suitable for pulmonary or nasal delivery. The methods comprise administration to a patient in need thereof the effective amount of an antiviral composition by pulmonary or nasal instillation.
IT 640281-90-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods for treatment of severe acute respiratory syndrome)
RN 640281-90-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:515518 CAPLUS
DN 141:38814
TI Process for the production of 2'-branched nucleosides
IN Storer, Richard; Moussa, Adel; Chaudhuri, Narayan; Waligora, Frank
PA Idenix Cayman Limited, Cayman I.
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052899	A2	20040624	WO 2003-US39643	20031212
	WO 2004052899	A3	20050331		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2509687	AA	20040624	CA 2003-2509687	20031212
AU 2003300901	A1	20040630	AU 2003-300901	20031212
US 2005020825	A1	20050127	US 2003-735408	20031212
EP 1585529	A2	20051019	EP 2003-812993	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1744903	A	20060308	CN 2003-80109576	20031212
JP 2006514993	T2	20060518	JP 2005-511773	20031212
NO 2005003115	A	20050818	NO 2005-3115	20050624
PRAI US 2002-432766P	P	20021212		
US 2003-466194P	P	20030428		
WO 2003-US39643	W	20031212		

OS CASREACT 141:38814
GI



I

Chelad ODP ✓

AB The present invention provides an improved process for preparing ss-D and ss-L 2'-C-methyl-nucleosides and 2'-C-methyl-3'-O-ester nucleosides, e.g. I, via glycosylation of methylribonolactone with nucleobases.

IT 640725-71-9P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for production of 2'-branched nucleosides via glycosylation of methylribonolactone with nucleobases)

RN 640725-71-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:453348 CAPLUS
DN 141:17578

McIntosh

TI Treatment of Flaviviridae infection with 2'-branched nucleosides and another mutation-inducing drug such as interferon

IN Sommadossi, Jean-Pierre; La Colla, Paolo; Standring, David; Bichko, Vadim; Ou, Kin

PA Idenix (Cayman) Limited, Cayman I.; Universita Degli Studi Di Cagliari

SO PCT Int. Appl., 166 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004046331	A2	20040603	WO 2003-US36714	20031117
	WO 2004046331	A3	20060302		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2506129	AA	20040603	CA 2003-2506129	20031117
	AU 2003298658	A1	20040615	AU 2003-298658	20031117
	US 2005031588	A1	20050210	US 2003-715729	20031117
	EP 1576138	A2	20050921	EP 2003-796412	20031117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016363	A	20051004	BR 2003-16363	20031117
	JP 2006519753	T2	20060831	JP 2004-553823	20031117
	CN 1849142	A	20061018	CN 2003-80108747	20031117
	NO 2005002920	A	20050815	NO 2005-2920	20050615
PRAI	US 2002-426675P	P	20021115		
	WO 2003-US36714	W	20031117		

OS MARPAT 141:17578

AB The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2'-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from serine to a different amino acid in the highly conserved consensus sequence, XRX<u>S</u>GXXXT, of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment. Thus, in bovine viral diarrhea virus (BVDV)-infected MDBK cells treated with β-D-2'-methylcytidine, viruses resistant to the nucleoside appeared. The drug resistance was associated with a mutation in the NS5B gene which resulted in an S405T substitution in the encoded RNA-dependent RNA polymerase. These mutant viruses were sensitive to Intron A (interferon α-2b). Intron A and β-D-2'-methylcytidine exhibited synergistic inhibitory activity on BVDV growth in MDBK cells.

IT 640281-90-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of Flaviviridae infection with 2'-branched nucleosides and another mutation-inducing drug such as interferon)

RN 640281-90-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Checked ODP

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:20697 CAPLUS
DN 140:87662
TI 2'- and 3'-nucleoside prodrugs for treating Flaviviridae infections
IN Sommadossi, Jean-pierre; La Colla, Paolo; Storer, Richard; Gosselin, Gilles
PA Idenix (Cayman) Limited, Cayman I.; Centre National de la Recherche Scientifique; Universita Degli Studi di Cagliari
SO PCT Int. Appl., 2498 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004003000	A2	20040108	WO 2003-IB3901	20030627
	WO 2004003000	A3	20041104		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2490200	AA	20040108	CA 2003-2490200	20030627
	AU 2003263412	A1	20040119	AU 2003-263412	20030627
	EP 1525209	A2	20050427	EP 2003-761749	20030627
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1678621	A	20051005	CN 2003-820690	20030627
	JP 2005537242	T2	20051208	JP 2004-517162	20030627
	CN 1761677	A	20060419	CN 2003-820501	20030627
	WO 2005020884	A2	20050310	WO 2004-US15395	20040514
	WO 2005020884	A3	20060622		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1656093	A2	20060517	EP 2004-776022	20040514
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	NO 2005000466	A	20050323	NO 2005-466	20050127
PRAI	US 2002-392350P	P	20020628		
	US 2002-392351P	P	20020628		
	US 2003-466194P	P	20030428		
	US 2003-470949P	P	20030514		
	WO 2003-IB3901	W	20030627		
	WO 2004-US15395	W	20040514		

OS MARPAT 140:87662
AB 2' And 3'-Prodrugs of 1'-, 2'-, 3'-, or 4'-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivs., are described which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C virus and viruses generally that replicate through an RNA-dependent RNA reverse transcriptase. Compds., compns., methods and uses are provided for the treatment of Flaviviridae infection, including HCV infection, that include the administration of an effective amount of the prodrugs of the invention, or their pharmaceutically acceptable salts or derivs. These drugs may optionally be administered in combination or alternation with further antiviral agents to prevent or treat Flaviviridae infections and other related conditions. Preparation of compds. of the invention is included.
IT 640725-71-9P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleoside prodrugs for treating Flaviviridae infections)
RN 640725-71-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

L4 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:20696 CAPLUS
DN 140:77365
TI Preparation of modified 2'- and 3'-nucleoside prodrugs for treating Flaviviridae infections
IN Sommadossi, Jean-pierre; La Colla, Paolo; Storer, Richard; Gosselin, Gilles
PA Idenix (Cayman) Limited, Cayman I.; Universita degli studi di Cagliari; Centre National de la Recherche Scientifique
SO PCT Int. Appl., 201 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002999	A2	20040108	WO 2003-IB3246	20030627
	WO 2004002999	A3	20040812		
	WO 2004002999	C1	20050217		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2490191	AA	20040108	CA 2003-2490191	20030627
	AU 2003247084	A1	20040119	AU 2003-247084	20030627
	EP 1523489	A2	20050420	EP 2003-761744	20030627
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1678621	A	20051005	CN 2003-820690	20030627
	JP 2005533817	T2	20051110	JP 2004-517158	20030627
	CN 1761677	A	20060419	CN 2003-820501	20030627
	WO 2005020884	A2	20050310	WO 2004-US15395	20040514
	WO 2005020884	A3	20060622		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				

10/775,408

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG
EP 1656093 A2 20060517 EP 2004-776022 20040514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
NO 2005000465 A 20050127 NO 2005-465 20050127
PRAI US 2002-392350P P 20020628
US 2002-392351P P 20020628
US 2003-466194P P 20030428
US 2003-470949P P 20030514
WO 2003-IB3246 W 20030627
WO 2004-US15395 W 20040514
OS MARPAT 140:77365
GI



I

AB 2' And/or 3' prodrugs of 1', 2', 3' or 4'-branched-nucleosides I, wherein R1-R3 are independently H, phosphate, alkyl, acyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonate ester, benzyl, wherein the Ph group is optionally substituted with one or more substituents, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, lipid, amino acid, carbohydrate, peptide, cholesterol; Y1 is hydrogen, bromo, chloro, fluoro, iodo, CN, OH, OR4, NH2, NHR4, NR4R5, SH or SR4; X1 and X2 are independently alkyl, CH3, CF3, CY3, 2-Br-Et, CH2F, CH2Cl, CH2CF3, CF2CF3, CY2CY3, CH2OH, alkenyl, alkynyl, COOH, COOR4, COO-alkyl, COO-aryl, CO-O-alkoxyalkyl, CONH2, CONHR4, CON(R4)2, halo, CN, N3, OH, OR4, NH2, NHR4, NR4R5, SH or SR5; Y is independently H, halo; and each R4 and R5 is independently hydrogen, acyl, alkyl, lower alkyl, alkenyl, alkynyl or cycloalkyl, and their pharmaceutically acceptable salts and derivs. are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compds. and compns. of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivs. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions. Thus, antiviral activity of β-D-2'-C-methyl-7-methyl-6-phenyl-3,3a,5,8a-tetrahydro-1,3,4,5,7a-penta-aza-s-indacen-8-one is reported.

IT 640281-90-9P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of modified and nucleoside prodrugs for treating flaviviridae infections)

RN 640281-90-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:20443 CAPLUS
DN 140:70984
TI 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
IN Sommadossi, Jean-Pierre; La Colla, Paolo
PA Idenix (Cayman) Limited, Cayman I.; Universita Degli Studi di Cagliari
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DT Patent
LA English
my app.
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002422	A2	20040108	WO 2003-US20431	20030627
	WO 2004002422	A3	20050407		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2489552	AA	20040108	CA 2003-2489552	20030627
	AU 2003248748	A1	20040119	AU 2003-248748	20030627
	US 2004077587 ✓	A1	20040422	US 2003-607909	20030627
	EP 1536804	A2	20050608	EP 2003-762183	20030627
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1678326	A	20051005	CN 2003-820701	20030627
	JP 2005533824	T2	20051110	JP 2004-518041	20030627
	WO 2005020884	A2	20050310	WO 2004-US15395	20040514
	WO 2005020884	A3	20060622		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1656093	A2	20060517	EP 2004-776022	20040514
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	NO 2005000490	A	20050127	NO 2005-490	20050127
PRAI	US 2002-392351P	P	20020628 ✓		
	US 2003-466194P	P	20030428		
	US 2003-470949P	P	20030514		
	WO 2003-US20431	W	20030627		
	WO 2004-US15395	W	20040514		

OS MARPAT 140:70984
AB The 3'-L-valine ester of β-D-2'-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compds., compns., methods and uses are provided for the treatment of flaviviridae, including HCV, that include the administration of an effective amount of val-mCyd or its salt,

ester, prodrug or derivative, optionally in a pharmaceutically acceptable carrier. In an alternative embodiment, val-mCyd is used to treat any virus that replicates through an RNA-dependent RNA polymerase. Several examples are provided of the pharmacol., mechanism of action, metabolism, side effects, and clin. efficacy of the title compound

IT 640281-90-9D, salts 642075-50-1 642075-51-2
642075-52-3 642075-53-4 642075-54-5
642075-55-6 642075-56-7 642075-57-8
642075-58-9 642075-59-0 642075-60-3
642075-61-4 642075-62-5 642075-63-6
642075-64-7 642075-65-8 642075-66-9
642075-67-0 642075-68-1 642075-69-2
642075-70-5 642075-71-6 642075-72-7
642075-74-9 642075-75-0 642075-76-1
642075-77-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ribofuranosylcytidine methylvaline ester combined with other antivirals for treatment of flaviviridae infections)

RN 640281-90-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 642075-50-1 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine, 4-methylbenzenesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 642075-51-2 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine, methanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 642075-52-3 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 642075-53-4 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, 2-hydroxy-1,2,3-propanetricarboxylate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 642075-54-5 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, propanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 141-82-2
CMF C3 H4 O4



RN 642075-55-6 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 642075-56-7 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, butanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 642075-57-8 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, benzoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 65-85-0
CMF C7 H6 O2



RN 642075-58-9 CAPLUS
CN L-Ascorbic acid, compd. with L-valine 3'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 50-81-7
CMF C6 H8 O6

Absolute stereochemistry.



RN 642075-59-0 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, 2-oxopentanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9

CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 328-50-7
CMF C5 H6 O5



RN 642075-60-3 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, 2,3-dihydroxypropyl phosphate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 57-03-4
CMF C3 H9 O6 P



RN 642075-61-4 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, formate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 642075-62-5 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 642075-63-6 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, propanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 79-09-4
CMF C3 H6 O2



RN 642075-64-7 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, hydroxyacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 79-14-1
CMF C2 H4 O3



RN 642075-65-8 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, 2-hydroxypropanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 50-21-5
CMF C3 H6 O3



RN 642075-66-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, 2-oxopropanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 127-17-3
CMF C3 H4 O3



RN 642075-67-0 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, ethanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 642075-68-1 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, (2Z)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 642075-69-2 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, 2-hydroxybenzoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 69-72-7
CMF C7 H6 O3



RN 642075-70-5 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, sulfate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 642075-71-6 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, nitrate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 7697-37-2
CMF H N O3



RN 642075-72-7 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, carbonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 463-79-6
CMF C H2 O3



RN 642075-74-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, hydrobromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HBr

RN 642075-75-0 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, hydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HI

RN 642075-76-1 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, carbonate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 463-79-6
CMF C H2 O3



RN 642075-77-2 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, phosphate (salt) (9CI) (CA

INDEX NAME)

CM 1

CRN 640281-90-9
CMF C15 H24 N4 O6

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



IT 640281-90-9P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(ribofuranosylcytidine methylvaline ester for treatment of flaviviridae infections)
RN 640281-90-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 640725-71-9P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(ribofuranosylcytidine methylvaline ester for treatment of flaviviridae infections)
RN 640725-71-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

=> d his

(FILE 'HOME' ENTERED AT 13:51:27 ON 08 DEC 2006)

FILE 'REGISTRY' ENTERED AT 13:51:54 ON 08 DEC 2006
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 30 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:52:32 ON 08 DEC 2006
L4 16 S L3